Company Performance Metrics
- Aruna Gambhir: Chief Executive Officer
- Sam Quezada: Co-founder & COO
CellSight is developing a suite of PET tracers targeted at visualizing immune response early in a patient's immunotherapy regimen.
Their lead PET imaging tracer targeted at imaging activated T cells is a Fluorine 18 labeled analog of an FDA approved drug ArabinoFuranosylGuanine [18F]F-AraG, trade name VisAcT. VisAcT does not care about the
type of immunotherapy regimen being administered – adoptive cell therapy, checkpoint inhibitors, cancer vaccines or a combination of immunotherapy and conventional medicines. VisAcT hones in on and images activated T cells that are critical to any immune modulated therapy.
CellSight's VisAcT PET tracer is currently undergoing clinical trials at University of California San Francisco and will be used to image cancer patients undergoing immunotherapy.
